Literature DB >> 25987179

Innovative treatments for lysosomal diseases.

Timothy M Cox1.   

Abstract

Striking therapeutic advances for lysosomal diseases have harnessed the biology of this organelle and illustrate its central rôle in the dynamic economy of the cell. Further Innovation will require improved protein-targetting or realization of therapeutic gene- and cell transfer stratagems. Rescuing function before irreversible injury, mandates a deep knowledge of clinical behaviour as well as molecular pathology – and frequently requires an understanding of neuropathology. Whether addressing primary causes, or rebalancing the effects of disordered cell function, true therapeutic innovation depends on continuing scientific exploration of the lysosome. Genuine partnerships between biotech and the patients affected by this extraordinary family of disorders continue to drive productive pharmaceutical discovery.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  chaperone; gene transfer; inhibitors of biosynthesis; innovation; lysosome; organelle; protein targeting; sphingolipids; substrate reduction; therapeutic

Mesh:

Year:  2015        PMID: 25987179     DOI: 10.1016/j.beem.2015.01.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  9 in total

Review 1.  Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review.

Authors:  Daniel Oder; Jonas Müntze; Peter Nordbeck
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

2.  The treatment of juvenile/adult GM1-gangliosidosis with Miglustat may reverse disease progression.

Authors:  Federica Deodato; Elena Procopio; Angelica Rampazzo; Roberta Taurisano; Maria Alice Donati; Carlo Dionisi-Vici; Anna Caciotti; Amelia Morrone; Maurizio Scarpa
Journal:  Metab Brain Dis       Date:  2017-06-03       Impact factor: 3.584

3.  Dyslipidaemia: Lysosomal acid lipase deficiency-a cautious leap forward.

Authors:  Carla E M Hollak; G Kees Hovingh
Journal:  Nat Rev Endocrinol       Date:  2015-10-27       Impact factor: 43.330

Review 4.  Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders.

Authors:  Maria Francisca Coutinho; Juliana Inês Santos; Sandra Alves
Journal:  Int J Mol Sci       Date:  2016-07-04       Impact factor: 5.923

Review 5.  Drug delivery in overcoming the blood-brain barrier: role of nasal mucosal grafting.

Authors:  Carlotta Marianecci; Federica Rinaldi; Patrizia Nadia Hanieh; Luisa Di Marzio; Donatella Paolino; Maria Carafa
Journal:  Drug Des Devel Ther       Date:  2017-01-27       Impact factor: 4.162

6.  Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain.

Authors:  Penelope J Hallett; Mylene Huebecker; Oeystein R Brekk; Elizabeth B Moloney; Emily M Rocha; David A Priestman; Frances M Platt; Ole Isacson
Journal:  Neurobiol Aging       Date:  2018-03-29       Impact factor: 4.673

Review 7.  The rapidly evolving view of lysosomal storage diseases.

Authors:  Giancarlo Parenti; Diego L Medina; Andrea Ballabio
Journal:  EMBO Mol Med       Date:  2021-01-18       Impact factor: 12.137

8.  Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: A multicenter experience.

Authors:  Rita Fischetto; Valentina Palladino; Maria M Mancardi; Thea Giacomini; Stefano Palladino; Alberto Gaeta; Maja Di Rocco; Lucia Zampini; Giuseppe Lassandro; Vito Favia; Maria E Tripaldi; Pietro Strisciuglio; Alfonso Romano; Mariasavina Severino; Amelia Morrone; Paola Giordano
Journal:  Mol Genet Genomic Med       Date:  2020-08-11       Impact factor: 2.183

Review 9.  Developments in the treatment of Fabry disease.

Authors:  Sanne J van der Veen; Carla E M Hollak; André B P van Kuilenburg; Mirjam Langeveld
Journal:  J Inherit Metab Dis       Date:  2020-03-02       Impact factor: 4.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.